Literature DB >> 10648941

Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers.

M Birchler1, G Neri, L Tarli, C Halin, F Viti, D Neri.   

Abstract

Angiogenesis, the formation of new blood vessels from pre-existing ones, is a characteristic process which underlies many diseases, including cancer, rheumatoid arthritis and blinding ocular disorders. Antibodies capable of selective targeting and occlusion of neovasculature would open diagnostic and therapeutic opportunities. We have recently demonstrated that phage-derived human antibody fragments with high affinity for the extra-domain B (ED-B) of fibronectin, a marker of angiogenesis, selectively localise in new-forming blood vessels upon intravenous injection. Here, we show that infrared fluorescence methodologies nicely complement radioactive techniques for the study of the antibody-mediated targeting of angiogenesis in a variety of animal models. Methods are presented for the construction and use of infrared fluorescence imagers, as well as for the production and characterisation of recombinant antibodies labeled with infrared fluorophores.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10648941     DOI: 10.1016/s0022-1759(99)00160-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  13 in total

Review 1.  Antibody vectors for imaging.

Authors:  Tove Olafsen; Anna M Wu
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

Review 2.  Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods.

Authors:  Markus Rudin; Martin Rausch; Markus Stoeckli
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

3.  The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies.

Authors:  David Sánchez-Martín; Angel M Cuesta; Valentina Fogal; Erkki Ruoslahti; Luis Alvarez-Vallina
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

4.  Optimization of the near-infrared fluorescence labeling for in vivo monitoring of a protein drug distribution in animal model.

Authors:  Huimin Qian; Yueqing Gu; Min Wang; Samuel Achilefu
Journal:  J Fluoresc       Date:  2008-08-29       Impact factor: 2.217

5.  A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels.

Authors:  A Palumbo; F Hauler; P Dziunycz; K Schwager; A Soltermann; F Pretto; C Alonso; G F Hofbauer; R W Boyle; D Neri
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

6.  Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging.

Authors:  Bishnu P Joshi; Thomas D Wang
Journal:  Cancers (Basel)       Date:  2010-06-11       Impact factor: 6.639

7.  Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis.

Authors:  Eveline Trachsel; Frank Bootz; Michela Silacci; Manuela Kaspar; Hartwig Kosmehl; Dario Neri
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

8.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Authors:  Kathrin Schwager; Manuela Kaspar; Frank Bootz; Roberto Marcolongo; Erberto Paresce; Dario Neri; Eveline Trachsel
Journal:  Arthritis Res Ther       Date:  2009-09-25       Impact factor: 5.156

Review 9.  Imaging aspects of the tumor stroma with therapeutic implications.

Authors:  Lian Narunsky; Roni Oren; Filip Bochner; Michal Neeman
Journal:  Pharmacol Ther       Date:  2013-10-14       Impact factor: 12.310

10.  In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences.

Authors:  Angel M Cuesta; David Sánchez-Martín; Laura Sanz; Jaume Bonet; Marta Compte; Leonor Kremer; Francisco J Blanco; Baldomero Oliva; Luis Alvarez-Vallina
Journal:  PLoS One       Date:  2009-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.